The DOI matches its Crossref record; 229 of the 229 references it cites were found in a registry or an index.
Metabolism of immune cells in cancer
Open accessAbstract
Through the successes of checkpoint blockade and adoptive cellular therapy, immunotherapy has become an established treatment modality for cancer. Cellular metabolism has emerged as a critical determinant of the viability and function of both cancer cells and immune cells. In order to sustain prodigious anabolic needs, tumours employ a specialized metabolism that differs from untransformed somatic cells. This metabolism leads to a tumour microenvironment that is commonly acidic, hypoxic and/or depleted of critical nutrients required by immune cells. In this context, tumour metabolism itself is a checkpoint that can limit immune-mediated tumour destruction. Because our understanding of immune cell metabolism and cancer metabolism has grown significantly in the past decade, we are on the cusp of being able to unravel the interaction of cancer cell metabolism and immune metabolism in therapeutically meaningful ways. Although there are metabolic processes that are seemingly fundamental to both cancer and responding immune cells, metabolic heterogeneity and plasticity may serve to distinguish the two. As such, understanding the differential metabolic requirements of the diverse cells that comprise an immune response to cancer offers an opportunity to selectively regulate immune cell function. Such a nuanced evaluation of cancer and immune metabolism can uncover metabolic vulnerabilities and therapeutic windows upon which to intervene for enhanced immunotherapy. This Review discusses our current understanding of adaptive and innate immune cell metabolism in the context of the tumour microenvironment, providing insight into the interaction of cancer cell metabolism and immune metabolism, as well as the potential for leveraging metabolic vulnerabilities to enhance the antitumour immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, HIF-2α directly upregulates PD-L1 expression by binding to the HRE in the PD-L1 promoter in ccRCC cells (Fig. 2C) [73].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation
Moon, J.-S., Hisata, S., Park, M. A., DeNicola, G. M., Ryter, S. W., Nakahira, K., & Choi, A. M. K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.046 · Cited by 379
Retracted5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Succinate is an inflammatory signal that induces IL-1β through HIF-1α
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., et al. (2013) · Nature · doi:10.1038/nature11986 · Cited by 4,176
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Mitochondrial TCA cycle metabolites control physiology and disease
Martínez-Reyes, I., & Chandel, N. S. (2020) · Nature Communications · doi:10.1038/s41467-019-13668-3 · Cited by 2,813
Physiological Roles of Mitochondrial Reactive Oxygen Species
Sena, L. A., & Chandel, N. S. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.025 · Cited by 2,632
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589
Cited by
Sorted by citations
Items 301–400 of 899
Yang, Y., Zhang, B., Xu, Y., Zhu, W., Zhu, Z., Zhang, X., Wu, W., Chen, J., & Yu, Z. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.08.028 · Cited by 18
Where lung cancer and tuberculosis intersect: recent advances
Fang, C., He, X., Tang, F., Wang, Z., Pan, C., Zhang, Q., Wu, J., Wang, Q., Liu, D., & Zhang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561719 · Cited by 18
Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy
Zhou, X., Deng, R., Liao, Z., Huang, X., Huang, J., Yang, H., Leong, K. W., & Zhong, Y. (2025) · Advanced Science · doi:10.1002/advs.202510004 · Cited by 26
Obesity-Related Fatty Acid and Cholesterol Metabolism in Cancer-Associated Host Cells
Ye, Y., Sun, X., & Lu, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.600350 · Cited by 19
Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy
Chen, X.-H., Chen, R., Shi, M.-Y., Tian, R.-F., Zhang, H., Xin, Z., Chen, Z., & Wang, X. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101309 · Cited by 18
Metabolic Regulation of CD8 + T Cells: From Mechanism to Therapy
Zheng, Y. Y., Wang, X., & Huang, M. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0040 · Cited by 19
Xu, C., & Xing, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01651-9 · Cited by 18
Zhao, T., Liu, S., Ding, X., Johnson, E. M., Hanna, N. H., Singh, K., Sen, C. K., Wan, J., Du, H., & Yan, C. (2022) · JCI Insight · doi:10.1172/jci.insight.156623 · Cited by 18
Metabolic control of cancer metastasis: role of amino acids at secondary organ sites
Karno, B. A., Edwards, D. N., & Chen, J. (2023) · Oncogene · doi:10.1038/s41388-023-02868-3 · Cited by 18
Chagovets, V., Starodubtseva, N. L., Tokareva, A., Novoselova, A., Patysheva, M. R., Larionova, I., Prostakishina, E. A., Rakina, M. A., Казакова, А., Topolnitskiy, E. B., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332043 · Cited by 19
Advances in Metabolic Regulation of Macrophage Polarization State
Liu, X., Xiang, R., Fang, X., Wang, G., & Zhou, Y. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2302828 · Cited by 19
Foxp3 + Treg-derived IL-10 promotes colorectal cancer-derived lung metastasis
Shiri, A. M., Fard-Aghaie, M. H., Bedke, T., Papazoglou, E. D., Sabihi, M., Zazara, D. E., Zhang, S., Lücke, J., Seeger, P., Evers, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-80437-8 · Cited by 18
mTOR‐dependent immunometabolism as Achilles' heel of anticancer therapy
Braun, C., & Weichhart, T. (2021) · European Journal of Immunology · doi:10.1002/eji.202149270 · Cited by 18
Jiang, K., Liu, H., Chen, X., Wang, Z., Wang, X., Gu, X., Tong, Y., Ba, X., Yu, H., Wu, J., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s513207 · Cited by 18
Fabiano, E. D., Poole, J. M., & Reinhart-King, C. A. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00892.2024 · Cited by 17
Zhao, Y., Pu, C., Liu, K., & Liu, Z. (2025) · Amino Acids · doi:10.1007/s00726-025-03456-3 · Cited by 17
DTL promotes melanoma progression through rewiring cell glucose metabolism
Lu, J.-J., Chen, F., Li, Y., Xu, X., Peng, C., Yu, N., Su, L., & Tang, L. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6648 · Cited by 17
New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes
Zhang, M., Zhou, Y., Xie, Z., Luo, S., Zhou, Z., Huang, J., & Zhao, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.914136 · Cited by 19
Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma
Huang, S., Hou, Y., Hu, M., Hu, J., & Liu, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-10087-4 · Cited by 16
Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Arbore, G., Albarello, L., Bucci, G., Punta, M., Cossu, A., Fanti, L., Maurizio, A., Mauro, F. D., Bilello, V., Arrigoni, G., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0356 · Cited by 18
Immunometabolism: a new dimension in immunotherapy resistance
Xiao, C., Xiong, W., Xu, Y., Zou, J. P., Zeng, Y., Liu, J., Peng, Y., Hu, C., & Wu, F. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1012-z · Cited by 18
Engineering metabolism to modulate immunity
Kapnick, S. M., Martin, C. A., & Jewell, C. M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115122 · Cited by 18
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy
Chen, C., Han, P., & Qing, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103579 · Cited by 17
Zhong, X., Wang, Y., He, X., Hu, Z., Hu, Z., Huang, H., Chen, J., Chen, K., Wei, P., Zhao, S., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06958-2 · Cited by 17
Bingbing, W., Yao, C., Wang, H., Dai, H., Tian, B., Li, D., Xu, F., Cheng, H., Xu, F., Sun, D., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123078 · Cited by 18
Zhang, Z., Liu, Q., Tan, J., Zhan, X., Liu, T., Wang, Y., Lu, G., Wu, M., & Zhang, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.002 · Cited by 17
Harnessing EV communication to restore antitumor immunity
Massaro, C., Min, W., Pegtel, D. M., & Baglio, S. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113838 · Cited by 17
DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma
Chen, M., Huang, B., Zhu, L., Wang, Q., Pang, Y. K., Cheng, M., Lian, H., Liu, M., Zhao, K., Xu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875648 · Cited by 17
Xiong, W., Xiao, L., Duan, R., Wang, Q., Xian, M., Zhang, C., Pan, S., Li, Y., Zhong, L., Qian, J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008979 · Cited by 16
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond
Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544532 · Cited by 18
Immune and metabolic checkpoints blockade: Dual wielding against tumors
Kazemi, M. H., Najafi, A., Karami, J., Ghazizadeh, F., Yousefi, H., Falak, R., & Safari, E. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107461 · Cited by 16
Guo, Y., Zheng, Z., Mao, S., Yang, F., Wang, R., Wang, H., Liu, J. T., Li, C., Wang, Q., Zhang, W., et al. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23475 · Cited by 16
Zhong, J., Sun, Z., Li, S., Liu, Y., Cao, Y., & Bao, J. (2023) · Discover Oncology · doi:10.1007/s12672-023-00718-y · Cited by 16
Wang, Y., Zhang, B., Xi, Q., Chen, C., Wang, Z., Li, F., Wang, S., Yang, W., Liang, X., Yu, Z., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102009 · Cited by 16
Zhang, X., Zhang, M., Song, L., Wang, S., Wei, X., Shao, W., & Song, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-46577-z · Cited by 16
Nanoparticle-Based Immunotherapy for Reversing T-Cell Exhaustion
Li, F., Wang, Y. J., Chen, D., & Du, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031396 · Cited by 17
Huang, L., Li, H., Zhang, C., Chen, Q., Liu, Z., Zhang, J., Luo, P., & Wei, T. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1620 · Cited by 18
Zhang, T., Lai, S., Cai, Y., Huang, Z. L., Li, Y., Chen, S., Zhang, Z., Ye, Z., Lai, X., Zhai, E., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.719613 · Cited by 16
Fu, L., Huang, Y. L., Hou, J., Sun, M., Wang, L., Wang, X., & Chen, L. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01696f · Cited by 16
Wu, C., Cui, Y., Liu, J., Ma, L., Xiong, Y., Gong, Y., Zhao, Y., Zhang, X., Chen, S., He, Q., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05399-9 · Cited by 16
Yang, R., Wang, Z., Li, J., Pi, X., Gao, R., Ma, J., Qing, Y., & Zhou, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707677 · Cited by 16
Wang, G., Wang, D., Xia, L., Lian, J., Zhang, Q., Shen, D., Wang, Z., & Dai, Y. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c21028 · Cited by 15
Krug, A., Ernst, L. M., Mhaidly, R., Ramis, J., Gustà, M. F., Bastús, N. G., Martinez-Turtos, A., Tosolini, M., Mascio, L. D., Tari, G., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c02860 · Cited by 15
High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma
Li, S.-W., Huang, J., Yang, F., Zeng, H.-P., Tong, Y., & Li, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-90507-w · Cited by 9
Yu, J., Zhang, Q., Li, J., Si, Z., Guo, Y., Xu, X., & Wu, K. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002159 · Cited by 16
Peritoneal resident macrophages in tumor metastasis and immunotherapy
Zhang, Y., Ouyang, D., Chen, Y. H., & Xia, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.948952 · Cited by 16
Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
Peng, L., Fang, H., Yang, X. J., & Zeng, X. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.847621 · Cited by 15
FLIM of NAD(P)H in Lymphatic Nodes Resolves T-Cell Immune Response to the Tumor
Izosimova, A. V., Shirmanova, M. V., Shcheslavskiy, V. I., Sachkova, D. A., Mozherov, A. M., Sharonov, G. V., Вадимовна, З. Е., & Yuzhakova, D. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415829 · Cited by 16
Development of a Triple-Negative Breast Cancer Leptomeningeal Disease Model in Zebrafish
Gopal, U., Monroe, J. D., Marudamuthu, A. S., Begum, S., Walters, B. J., Stewart, R. A., Washington, C. W., Gibert, Y., & Zachariah, M. A. (2023) · Cells · doi:10.3390/cells12070995 · Cited by 14
Patel, C. H., Dong, Y. W., Koleini, N., Wang, X., Dunkerly-Eyring, B. L., Wen, J., Ranek, M. J., Bartle, L. M., Henderson, D. B., Sagert, J. G., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167829 · Cited by 13
Self-citationElmetwalli, A., Kamosh, N. H., Safty, R. E., Youssef, A. I., Salama, M., Abdel-Razek, K. M., & El-Sewedy, T. (2023) · Medical Oncology · doi:10.1007/s12032-023-02236-x · Cited by 15
Ge, Q., Wang, Z., Yu, J., Feng, X., Li, J., Zhang, X., Wang, S., Wang, L., & Chen, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-82486-5 · Cited by 15
Guo, Y., Jiang, T., Liang, S., Wang, A., Li, J., Jia, Y., Li, Q., Yin, J., Bai, S., & Li, J. (2025) · Advanced Science · doi:10.1002/advs.202412507 · Cited by 15
Immunotherapeutic Approaches for Glioblastoma Treatment
Yaghi, N. K., & Gilbert, M. R. (2022) · Biomedicines · doi:10.3390/biomedicines10020427 · Cited by 16
Gene expression is a poor predictor of steady‐state metabolite abundance in cancer cells
Li, H., Barbour, J. A., Zhu, X., & Wong, J. W. H. (2022) · The FASEB Journal · doi:10.1096/fj.202101921rr · Cited by 17
Bacteria-Mediated Modulatory Strategies for Colorectal Cancer Treatment
Mueller, A., Brockmueller, A., Fahimi, N., Ghotbi, T., Hashemi, S., Sadri, S., Khorshidi, N., Kunnumakkara, A. B., & Shakibaei, M. (2022) · Biomedicines · doi:10.3390/biomedicines10040832 · Cited by 17
Guglietta, S., & Krieg, C. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101012 · Cited by 18
Lu, Y., Zhou, C., Li, J., Liu, L., Liu, X., Shen, L., Lai, X., Gu, H., Zhang, Z., & Qian, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114595 · Cited by 14
Lattanzi, C., Bianchetto-Aguilera, F. M., Donini, M., Pettinella, F., Caveggion, E., Castellucci, M., Gasperini, S., Mariotti, B., Signoretto, I., Cantini, M., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2521396 · Cited by 16
Tumor Microenvironment Metabolism‐Modulating Nanomedicines for Enhancing Anti‐Tumor Immunity
Chen, J., Fei, S., Cao, Z., Liu, X., Ji, W., Chen, H., Niu, Y., & Yang, Z. (2025) · Small · doi:10.1002/smll.202509685 · Cited by 17
The Fast‐Growing Field of Cancer Immunotherapy Based on Aggregation‐Induced Emission
Lin, Z., He, T., Kang, M., Xie, W., Wang, D., & Tang, B. Z. (2025) · Aggregate · doi:10.1002/agt2.70189 · Cited by 15
CLIM-TIME identifies metastatic microenvironment modulators for T cell therapy response
Wang, Y., Hu, W., Xia, R., Yang, X., Gu, Y., Ning, Z., Yang, T., Yu, C., Zhang, L., Li, D., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.042 · Cited by 14
Yang, W., Zhao, Y., Ge, Q., Wang, X., Yang, J. X., Zhao, J., Liu, G., Huang, H., Cheng, F., Wang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947080 · Cited by 14
Du, Z., Su, J., Lin, S., Chen, T., Gao, W., Wang, M., Li, Y., Dong, W., Hu, Z., Gao, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.010 · Cited by 14
Targeting gut microbiota for immunotherapy of diseases
Yu, Y., Liu, X., Liao, C., Yu, R., Wang, X., Li, M., & Wang, Y. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03770-x · Cited by 14
Sun, L., Meng, H., Liu, T., Zhao, Q., Xia, M., Zhao, Z., Qian, Y., Hao, C., Zhong, X., Chai, K., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107785 · Cited by 14
Oriuchi, N., Sugawara, S., & Shiga, T. (2020) · Biomedicines · doi:10.3390/biomedicines8090371 · Cited by 15
Li, W., Meng, X., Yuan, H., Xiao, W., & Zhang, X. (2022) · IUBMB Life · doi:10.1002/iub.2596 · Cited by 14
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities
Yan, C., Zhao, M., Wei, Y.-N., & Zhao, X. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.02.001 · Cited by 15
Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy
Zhou, B., Yang, Y., Kang, Y., Hou, J., & Yang, Y. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01384-x · Cited by 15
The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy
Fujiwara, Y., Kato, T., Hasegawa, F., Sunahara, M., & Tsurumaki, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15020207 · Cited by 16
Kang, X., Li, D., & Sun, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1647737 · Cited by 13
Zhao, K., Cui, S., Wang, N., Wei, Q., Wang, X., Hou, K., Zhu, J., & Kong, F. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07748-4 · Cited by 14
Nikkhoo, E., Dinari, M., Lützenkirchen, J., & Monjezi, B. H. (2026) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2026.103898 · Cited by 13
Luo, L., Li, A., Fu, S., Du, W. T., He, L.-N., Zhang, X., Wang, Y., Zhou, Y., Yunpeng, Y., Li, Z., et al. (2022) · Immunologic Research · doi:10.1007/s12026-022-09335-3 · Cited by 13
Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer
Guo, D., Ye, L., Wu, W., Yu, X., & Jin, K. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023045 · Cited by 13
Xu, Y., Xue, D., Kyani, A., Bankhead, A., Roy, J., Ljungman, M. E., & Neamati, N. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00069 · Cited by 15
Research progress of cell membrane biomimetic nanoparticles for circulating tumor cells
Zhang, Y., & Wang, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1389775 · Cited by 14
Li, X., Zhou, L., Xu, X., Liu, X.-Y., Wu, W., Feng, Q., & Tang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1392241 · Cited by 13
Zeng, J., Liu, J., Zhao, N., Wong, I. N., & Huang, R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134450 · Cited by 14
Chen, H., Zhang, X., Wang, Z., Luo, J., Liu, Y., & Shao, R. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05497-5 · Cited by 13
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Yue, T., Sun, Y., Dai, Y., & Jin, F. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101256 · Cited by 15
Biomimetic calcium-chelation nanoparticles reprogram tumor metabolism to enhance antitumor immunity
Wang, Z., Wu, M. T., Jiang, Y., Zhou, J., Chen, S., Wang, Q., Sun, H., Deng, Y., Zhou, Z., & Sun, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.046 · Cited by 15
MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells
Karsten, S., Fiskesund, R., Zhang, X., Marttila, P., Sanjiv, K., Pham, T. M., Rasti, A., Bräutigam, L., Almlöf, I., Marcusson‐Ståhl, M., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00854-4 · Cited by 12
Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma
Hong, S., Zhang, Y., Cao, M., Lin, A., Yang, Q., Zhang, J., Luo, P., & Guo, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.762478 · Cited by 13
Essential amino acids deprivation is a potential strategy for breast cancer treatment
Zhao, Y., Pu, C., & Liu, Z. (2022) · The Breast · doi:10.1016/j.breast.2022.02.009 · Cited by 13
The critical function of metabolic reprogramming in cancer metastasis
Xie, S., Pan, J., Xu, J., Zhu, W., & Qin, L. (2022) · Aging and Cancer · doi:10.1002/aac2.12044 · Cited by 13
Li, H., Wu, Z., Zhang, Y., Lu, X., & Miao, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1201297 · Cited by 13
The Breast Tumor Microenvironment: Could Silicone Breast Implant Elicit Breast Carcinoma?
Fleury, E. D. F. C., Nimir, C., & D’Alessandro, G. S. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s294166 · Cited by 13
The tumor microenvironment: adding pieces to the puzzle
Aguilar‐Cázares, D., Perez-Medina, M., Benito-Lopez, J. J., Galicia-Velasco, M., Meneses-Flores, M., Camarena, Á., & López-González, J. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1731338 · Cited by 13
Navigating immune cell immunometabolism after liver transplantation
Zhang, W., Liu, Z., & Xu, X. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103227 · Cited by 12
Intrinsic and extrinsic factors determining natural killer cell fate: Phenotype and function
Zhi, L., Wang, X., Gao, Q., He, W., Shang, C., Guo, C., Niu, Z., Zhu, W., & Zhang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115136 · Cited by 12
Ye, P., Yusufu, R., Guan, Z., Chen, T., Li, S., Feng, Y., Zeng, X., Lu, J., Luo, M., & Wei, F. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091131 · Cited by 12
Single-cell sequencing in diffuse large B-cell lymphoma: C1qC is a potential tumor-promoting factor
Gao, G., Sun, N., Zhang, Y., Li, J., Jiang, Y., Chen, N., Tang, Y., & Shi, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113319 · Cited by 12
Rosenlehner, T., Pennavaria, S., Akçabozan, B., Jahani, S., O’Neill, T. J., Krappmann, D., Straub, T., Kranich, J., & Obst, R. (2024) · Science Signaling · doi:10.1126/scisignal.adi8753 · Cited by 12
Hypoxia studies in non‑small cell lung cancer: Pathogenesis and clinical implications (Review)
Zhou, S., Sun, J., Zhu, W., Yang, Z., Wang, P., & Zeng, Y. (2024) · Oncology Reports · doi:10.3892/or.2024.8862 · Cited by 12
Cheng, C., Zha, Q., Sun, L., Cui, T., Guo, X., Xing, C., Chen, Z., Ji, C., Liang, S., Tao, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02120-8 · Cited by 14
Shende, S., Rathored, J., & Budhbaware, T. (2025) · Discover Oncology · doi:10.1007/s12672-025-02238-3 · Cited by 15
Chen, L., Ma, S., Wu, H., Zheng, L., Yi, Y., Liu, G., Li, B., Sun, J., Du, Y., Wang, B., et al. (2025) · Advanced Science · doi:10.1002/advs.202412434 · Cited by 13
Shi, T., Shao, J., Ding, Y., Tang, H., Tan, X., Zhou, S., Yu, S., Wang, X., Yu, G., Feng, N., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.011 · Cited by 13
Metadata
- Authors
- Leone, R. D., & Powell, J. D.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Powell, Jonathan D.
- Venue
- Nature Reviews Cancer
- Published
- 2020-07-06
- Volume
- 20
- Issue
- 9
- Pages
- 516-531
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC8041116
- OpenAlex
- W3040651070
- Semantic Scholar
- 9e54633c23933564226222b58eee14bffccca97c
- Cited by
- 877
- References
- 228
- Citations by year
- 2026: 137 · 2025: 168 · 2024: 141 · 2023: 135 · 2022: 185 · 2021: 98 · 2020: 12
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA229451, R01CA226765)
- National Institute of Allergy and Infectious Diseases (R01AI077610)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- immune cell metabolism, cancer metabolism, tumor microenvironment, tumor acidosis, tumor hypoxia, nutrient depletion, adaptive immunity, innate immunity, metabolic heterogeneity, metabolic plasticity, metabolic vulnerability, immunotherapy, antitumor immunity
- MeSH terms
- Animals, Humans, Immune System, Immunotherapy, Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
